<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03966625</url>
  </required_header>
  <id_info>
    <org_study_id>DSBUS</org_study_id>
    <nct_id>NCT03966625</nct_id>
  </id_info>
  <brief_title>Serological Identification of Celiac Disease in Kids</brief_title>
  <acronym>SICK</acronym>
  <official_title>Serological Identification of Celiac Disease in Kids (Swedish: Screening för Celiaki på Barnmottagning)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vastra Gotaland Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to examine the feasibility of incorporating serological celiac disease&#xD;
      (CD) screening into general pediatric outpatient clinics in Sweden and through structured&#xD;
      monitoring examine the effects of diagnosing and treating screening-detected CD.&#xD;
&#xD;
      Screening will be tailored to general pediatric outpatient clinics in the Gothenburg&#xD;
      metropolitan area with the goal to screen 1000 children over four months. Screening for CD&#xD;
      will be carried out by measuring tissue transglutaminase autoantibodies (TGA) in blood.&#xD;
      Children who are persistently TGA positive will be enrolled into a 6-12-month follow-up&#xD;
      protocol responsible for diagnosing CD, installation of gluten-free diet and to assess their&#xD;
      short-term impact upon the child's wellbeing. Other components to assess include (I) the&#xD;
      feasibility to incorporate CD screening into busy pediatric practices; (II) parental/child&#xD;
      interest in, and satisfaction with, participating in a CD screening program and (III)&#xD;
      identifying key considerations for a possible scaled-up, broad-based, CD screening.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 4, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants diagnosed with celiac disease</measure>
    <time_frame>Assessed after 6-12 months of follow-up</time_frame>
    <description>Celiac disease diagnosed according to European pediatric (ESPGHAN) guidelines</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants identified with celiac disease autoimmunity</measure>
    <time_frame>Assessed after performed two tests of TTG (apprx. 1-2 months after enrollment)</time_frame>
    <description>Celiac disease autoimmunity defined by having two consecutive positive tests for tissue transglutaminase (TTG) autoantibodies</description>
  </secondary_outcome>
  <enrollment type="Actual">496</enrollment>
  <condition>Celiac Disease in Children</condition>
  <condition>Pediatric Disorder</condition>
  <condition>Health, Subjective</condition>
  <condition>Growth Delay</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>tissue transglutaminase autoantibodies</intervention_name>
    <description>celiac disease-specific autoantibodies</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients at pediatric outpatient clinics in Gothenburg metro area&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 2-17 years old&#xD;
&#xD;
          -  Patient at pediatric outpatient clinics in Gothenburg metro area&#xD;
&#xD;
          -  Parental and adolescent consent to screening&#xD;
&#xD;
        Exclusion Criteria for serological screening:&#xD;
&#xD;
          -  Established celiac disease diagnosis&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Queen Slivia Children's Hosptial</name>
      <address>
        <city>Gothenburg</city>
        <zip>41650</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BUMM Hisingen</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 25, 2019</study_first_submitted>
  <study_first_submitted_qc>May 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2019</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Karl Mårild</investigator_full_name>
    <investigator_title>Pediatrican, associate professor</investigator_title>
  </responsible_party>
  <keyword>screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoantibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will not be shared in accordance with the ethical approval of this study</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

